5-azacytidine and decitabine monotherapies of myelodysplastic disorders (Q36250201)

13 August 2017

1 reference

title

5-azacytidine and decitabine monotherapies of myelodysplastic disorders (English)

1 reference

13 August 2017

Jim R Kuykendall

1

1 reference

PubMed ID

16144884

13 August 2017

language of work or name

English

0 references

publication date

6 September 2005

1 reference

Annals of Pharmacotherapy

13 August 2017

1 reference

13 August 2017

39

1 reference

13 August 2017

10

1 reference

13 August 2017

1700-1709

1 reference

DNA methylation and cancer

13 August 2017

1 reference

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

21 January 2018

1 reference

5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

21 January 2018

1 reference

Reactivating the expression of methylation silenced genes in human cancer

21 January 2018

1 reference

Epigenetics: The Role of Methylation in the Mechanism of Action of Tumor Suppressor Genes

21 January 2018

1 reference

21 January 2018

1 reference

DNA methylation in haematological malignancies: the role of decitabine

21 January 2018

1 reference

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

21 January 2018

1 reference

Epigenetic targets in hematopoietic malignancies

21 January 2018

1 reference

Reactivation of silenced genes and transcriptional therapy

21 January 2018

1 reference

Targeted therapies in myelodysplastic syndromes: ASH 2003 review

21 January 2018

1 reference

Demethylation of DNA by decitabine in cancer chemotherapy

21 January 2018

1 reference

A new theory of carcinogenesis

21 January 2018

1 reference

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

DNA methylation and gene activity

21 January 2018

1 reference

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

21 January 2018

1 reference

Cancer epigenetics comes of age

21 January 2018

1 reference

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension

21 January 2018

1 reference

Correlation between Hypomethylation of DNA and Expression of Globin Genes in Friend Erythroleukemia Cells

21 January 2018

1 reference

Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine

21 January 2018

1 reference

Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2'-deoxycytidine

21 January 2018

1 reference

Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription

21 January 2018

1 reference

Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

21 January 2018

1 reference

DNA methyltransferase inhibitors-state of the art.

21 January 2018

1 reference

Cell cycle effects and cellular pharmacology of 5-AZA-2?-deoxycytidine

21 January 2018

1 reference

Effect of trna from 5-azacytidine-treated hamster fibrosarcoma cells on protein synthesis in vitro in a cell-free system

21 January 2018

1 reference

Inhibition of protein synthesis in 5-azacytidine-treated HeLa cells

21 January 2018

1 reference

Drug effects on nucleic acid modification. I. A specific effect of 5-azacytidine on mammalian transfer RNA methylation invivo

21 January 2018

1 reference

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

Epigenetic cancer therapies: DNA methyltransferase inhibitors

21 January 2018

1 reference

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

21 January 2018

1 reference

Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours

21 January 2018

1 reference

Kinetics of phosphorylation of 5-aza-2′-deoxycytidine by deoxycytidine kinase

21 January 2018

1 reference

Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene

21 January 2018

1 reference

Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine

21 January 2018

1 reference

Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine

21 January 2018

1 reference

Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene

21 January 2018

1 reference

Proposals for the classification of the myelodysplastic syndromes

21 January 2018

1 reference

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

Epidemiological and etiological aspects of myelodysplastic syndromes

21 January 2018

1 reference

New approaches to the treatment of myelodysplasia.

21 January 2018

1 reference

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes

21 January 2018

1 reference

Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience

21 January 2018

1 reference

The tumorigenicity of 5-azacytidine in the male Fischer rat.

21 January 2018

1 reference

Carcinogenicity and haemoglobin synthesis induction by cytidine analogues

21 January 2018

1 reference

Teratogenicity of 5‐azacytidine in the Sprague‐Dawley rat

21 January 2018

1 reference

Effect of 5-azacytidine administration during very early pregnancy.

21 January 2018

1 reference

Teratogenic effects of the demethylating agent 5-aza-2'-deoxycytidine in the Swiss Webster mouse

21 January 2018

1 reference

Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1E612

1 reference

13 August 2017

1 reference

PubMed ID

16144884